<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04484402</url>
  </required_header>
  <id_info>
    <org_study_id>IBCE_LSC</org_study_id>
    <nct_id>NCT04484402</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells</brief_title>
  <official_title>Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Limbal Stem Cells (Corneal Epithelial Stem Cells) or Adipose-derived Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belarusian State Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with inflammatory-dystrophic diseases of the cornea using autologous
      limbal stem cells (corneal epithelial stem cells) or adipose-derived mesenchymal stem cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to treat inflammatory and dystrophic diseases of the cornea perilimbal injections of
      cultured autologous stem cells are performed. We use corneal (limbal) epithelial stem cells
      (LSC) or mesenchymal stem cells derived from adipose tissue (ADSC) and further mixed with
      sodium hyaluronate 1%
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2016</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cured patients</measure>
    <time_frame>2 month</time_frame>
    <description>Number of patients cured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>MSC/LSC application related adverse events assessed by blood count, liver and function tests</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Corneal Ulcer</condition>
  <condition>Corneal Disease</condition>
  <condition>Corneal Dystrophy</condition>
  <arm_group>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>limbal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived limbal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stem cells</intervention_name>
    <description>Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution</description>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>limbal stem cells</intervention_name>
    <description>Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution</description>
    <arm_group_label>limbal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard treatment</intervention_name>
    <description>Standard treatment according to the Clinical protocols</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>limbal stem cells</arm_group_label>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  inflammatory-dystrophic diseases of the cornea:

               1. Epithelial defects of the cornea, ulcerative keratitis of various etiology,
                  resistant to standard methods of treatment

               2. Dystrophic diseases of the cornea, accompanied by edema

               3. Burns of the cornea

               4. Neurotrophic forms of keratitis

               5. Persistent post-traumatic, postoperative, contusion keratitis and keratopathy

        Exclusion Criteria:

          1. Pregnancy.

          2. Viral hepatitis B and C, HIV, tubeculosis and other chronic viral and bacterial
             infections.

          3. Cancer or leukemia

          4. Any diseases in the stage of decompensation.

          5. Mental disorders.

          6. Anomalies of eye refraction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Volotovski, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Head of the Lab of Institute of Biophysics and Cell Engineering</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liudmila Marchenko, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Head of the Department of eyes diseases of Belarusian State Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zinaida Kvacheva</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leading researcher, Institute of Biophysics and Cell Engineering</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</name>
      <address>
        <city>Minsk</city>
        <zip>220072</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corneal Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Ulcer</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

